Developments in selective small molecule ATP-targeting the serine/threonine kinase Akt/PKB

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The serine/threonine kinase Akt (protein kinase B) is vital for cell survival and proliferation.
• Unregulated activation of the Phosphatidylinositol 3-kinase (PI3K)/Akt pathway is common in many human cancers, making Akt a significant therapeutic target.
• Existing Akt inhibitors show potent activity but often lack selectivity against other kinases like PKA and PKC.

Purpose of the Study:

• To review recent advances in the development of selective ATP-competitive inhibitors for Akt.
• To summarize novel approaches for designing Akt inhibitors with enhanced selectivity, bioavailability, and potency.

Main Methods:

• Review of recent scientific literature on Akt inhibitors.
• Analysis of diverse structural features of reported Akt inhibitors.
• Evaluation of biological data for selective ATP-competitive inhibitors.

Main Results:

• Several classes of Akt inhibitors, including ATP-competitive, PI analogs, and allosteric inhibitors, have been developed.
• Many inhibitors demonstrate nanomolar potency against Akt.
• Selectivity remains a challenge, with some inhibitors affecting other kinases.

Conclusions:

• Selective ATP-competitive inhibitors represent a promising strategy for Akt-targeted cancer therapy.
• Further research into novel approaches is needed to design inhibitors with improved selectivity, bioavailability, and potency.
• Developing highly selective Akt inhibitors could lead to more effective and safer cancer treatments.